Cisplatin (CDDP)

DRUG3 trials

Sponsors

M.D. Anderson Cancer Center, GlaxoSmithKline, Sun Yat-sen University

Conditions

Lung Cancer, Non-Small CellLymphomaMetastatic Breast CancerRecurrent Breast Cancer

Phase 1

Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer

TerminatedNCT00455572

GlaxoSmithKlineLung Cancer, Non-Small Cell

Start: 2007-05-11End: 2013-08-08Updated: 2017-05-15

Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer

RecruitingNCT06900647

Sun Yat-sen UniversityMetastatic Breast Cancer, Recurrent Breast Cancer

Start: 2025-01-01End: 2028-06-30Target: 20Updated: 2025-04-02

Phase 3

Combination Chemotherapy in Treating Patients With Lymphoma

CompletedNCT00002835

M.D. Anderson Cancer CenterLymphoma

Start: 1995-10-30End: 2004-02-04Updated: 2018-11-15

Related Papers

Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer.

2015-10-0148 citations